Search
Research
Maternal smoking during pregnancy and the risk of childhood type 1 diabetes in Western AustraliaThe aim of this study was to investigate the association between maternal smoking during pregnancy and type 1 diabetes in the offspring, using complete...
Research
The effect of short-term use of the Guardian RT continuous glucose monitoring system on fear of hypoglycaemia in patients with type 1 diabetes mellitusThis study examines whether the short-term use of a continuous glucose monitor can reduce the fear of hypoglycaemia in individuals with type 1 diabetes...
Research
The effect of oral insulin on subcutaneous insulin requirements and glycaemia in T1DMLiz Tim Davis Jones MBBS FRACP PhD MBBS DCH FRACP MD Co-director of Children’s Diabetes Centre Co-head, Diabetes and Obesity Research Co-director of

News & Events
What life is like living with type 1 diabetesEvery decision a child with type 1 diabetes makes can impact on their blood glucose levels.
Research
Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovationWhile advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future.
Research
Clinical Outcomes with MiniMedTM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 DiabetesAdvanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited.
Research
Hybrid Closed-Loop Versus Manual Insulin Delivery in Adults With Type 1 Diabetes: A Post Hoc Analysis Using the Glycemia Risk IndexGlycemia risk index (GRI) is a novel composite metric assessing overall glycemic risk, accounting for both hypoglycemia and hyperglycemia and weighted toward extremes. Data assessing GRI as an outcome measure in closed-loop studies and its relation with conventional key continuous glucose monitoring (CGM) metrics are limited.
Research
In safe hands: child health data storage, linkage and consent for useWhile there is potential for societal benefit from linkage and integration of large datasets, there are gaps in our understanding of the implications for children and young people, and limited inclusion of their views within this discourse. We aimed to understand the views and expectations of children, young people and their parents/caregivers in Aotearoa New Zealand regarding child health data storage, linkage and consent for use.
Research
Socioeconomic status and diabetes technology use in youth with type 1 diabetes: a comparison of two funding modelsTechnology use, including continuous glucose monitoring (CGM) and insulin pump therapy, is associated with improved outcomes in youth with type 1 diabetes (T1D). In 2017 CGM was universally funded for youth with T1D in Australia. In contrast, pump access is primarily accessed through private health insurance, self-funding or philanthropy.
Research
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data NetworkThe relationship between diabetic ketoacidosis (DKA) at diagnosis of type 1 diabetes and long-term glycemic control varies between studies. We aimed, firstly, to characterize the association of DKA and its severity with long-term HbA1c in a large contemporary cohort, and secondly, to identify other independent determinants of long-term HbA1c.